Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
about
Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction modelRole of mTOR in podocyte function and diabetic nephropathy in humans and mice.Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin.TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.Nutrient sensing, autophagy, and diabetic nephropathy.Understanding the mechanisms of proteinuria: therapeutic implicationsProtective effects of low-dose rapamycin combined with valsartan on podocytes of diabetic rats.Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.Autophagy and metabolic changes in obesity-related chronic kidney disease.mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.The podocyte as a target for therapies--new and old.The struggle for energy in podocytes leads to nephrotic syndrome.Proteinuria after kidney transplantation.Insulin signalling to the kidney in health and disease.mTOR controls kidney epithelia in health and disease.Targeting mTOR Signaling Can Prevent the Progression of FSGS.Renal cell carcinoma: new insights and challenges for a clinician scientist.Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy.mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.Podocyte autophagic activity plays a protective role in renal injury and delays the progression of podocytopathies.Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling.Conversion to sirolimus in pediatric renal transplant patients: a single-center experience.mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside.microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice.mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimusThe podocyte as a direct target of immunosuppressive agents
P2860
Q28731390-A30C3F8D-2399-4DAB-BAE2-C1C88351C3CEQ30500731-C6584E3B-94C5-4A33-9745-54AC8D0F08EEQ33723730-D7DE7808-A79B-4010-A863-D89463121FAAQ35354812-86EC8608-A706-4936-BEBF-1102AF576CC8Q35612372-6D7CC4B8-0AA6-4B22-9581-C315DC3F7231Q36100123-79C6E516-94A4-4772-B578-98E81E438089Q36183003-48E6AEA5-7F7D-4A29-AA3F-671C07CF5B27Q36874564-BA0C1567-BF1E-4E4B-8C5F-E1375B751D07Q37270835-821BBE73-ABD9-401B-895C-53A8B0025BEBQ37365132-C36BA2AF-C335-4564-AAE5-6ACB3AEF6375Q37951800-5B07034C-93DE-40B2-8C00-EE77ED54AB0EQ37995467-9C0FE1BD-EE41-4E89-B63F-4EEF99B92B23Q38012182-8A1DF543-75B6-490C-A504-D3B80707B407Q38063325-FD6349D1-08A7-4D82-82D2-BBCD7ED5D1F8Q38185017-C0D46FE6-540C-4F7A-A365-C24F587E8050Q38922365-9547737C-B252-4072-A8E1-073F1F69FE45Q39222755-BC151855-3687-4606-B8F6-F9B6E8407EE9Q41854722-8300DB5E-FF28-4360-AA75-4CE05A034CD4Q41912848-5D42E5C3-5DD5-44C3-BCEB-4143E9EEBCC5Q41921297-99011A3D-BDAE-4905-AFAF-6AC46BA6134EQ42068754-5D87EDE6-BC97-4099-A9AB-8676A6046CA9Q43808149-376A8A6E-099C-4232-80E8-D1D87860BCC6Q46764150-1075E031-9A68-40E1-950C-6466F1DE9AB6Q49353844-57D7BAB6-5620-409B-B421-804BCC16ED5DQ53048992-B00121CE-F030-4DD4-A72D-93D04A4E9241Q54351691-443458AF-5C2F-4174-8209-792EAD12E079Q56035477-5B0CA57A-8C07-496A-9125-57A236B9705EQ58177753-2201E066-2997-41A4-9E16-191764ADCA57
P2860
Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@en
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@nl
type
label
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@en
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@nl
prefLabel
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@en
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@nl
P2093
P2860
P50
P356
P1476
Rapamycin has dual opposing ef ...... t a matter of podocyte damage?
@en
P2093
Immaculada Herrero-Fresneda
Josep M Cruzado
Josep M Grinyó
Juan Torras
Maria Flaquer
Nuria Lloberas
P2860
P304
P356
10.1093/NDT/GFP367
P407
P577
2009-08-11T00:00:00Z